Comparison of patient comfort between iodixanol and iopamidol in contrast-enhanced computed tomography of the abdomen and pelvis: a randomized trial

Weiland, Frederick L.; Martí‐Bonmatí, Luis; Lim, Lauren; Becker, Christoph R.

doi:10.1177/0284185113505277

Cited by 8 publications

(7 citation statements)

References 30 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, none of these results reached the predefined cut off for statistical significance. Our results fairly compares with previously published data from RCTs documenting less patients’ discomfort, minor frequency of AEs and equivalent or higher quality image in association with iodixanol compared with low osmolar CM (Gharekhanloo & Torabian, ; Weiland et al, ; Xiao et al, ). Similarly, results from studies of iodine CM intra‐arterial injection tend to favor iodixanol over low osmolar CM agents by safety profile (Manke et al, ; Manninen et al, ; Rosenberg et al, ; Svensson et al, ).…”

Section: Discussionsupporting

confidence: 90%

“…Similarly, results from studies of iso‐osmolar versus low osmolar CM for the intra‐venous (i.v.) route have been fairly consistent in supporting less frequent discomfort, better safety profile, and greater enhancement of the hepatic, aorta, and portal vein (Gharekhanloo & Torabian, ; Weiland, Marti‐Bonmati, Lim, & Becker, ; Xiao et al, ) in patients receiving iso‐osmolar CM. Risk of CIN development defined at the single patient level upon baseline estimation of the glomerular filtration rate (eGFR) have been repeatedly considered in trials of CIN following iodine CM administration in course of CT scan, with inconsistent results (Davenport, Khalatbari, Cohan, et al, ; Davenport, Khalatbari, Dillman, et al, ; Kim et al, ; Kuhn et al, ; Lima et al, ; McDonald, McDonald, Bida, ; McDonald, McDonald, Comin, ; Thomsen & Morcos, ; Utsunomiya et al, ; Weisbord et al, ).…”

Section: Introductionmentioning

confidence: 76%

See 1 more Smart Citation

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Terrenato¹,

Sperati²,

Musicco³

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 76%

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Terrenato¹,

Sperati²,

Musicco³

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Phagocytosis of macrophages is inhibited by HOCM and LOCM. On the other hand, chemotaxis of granulocytes was not affected by any CM after urography (80,81). The ionic HOCM has an anticoagulant effect, as demonstrated in an experimental study on the thrombogenic effects of various CM in angiographic catheters (82).…”

Section: Effects Of Contrast Media On Blood/ Hemorheologic Effectsmentioning

confidence: 93%

“…Iodine-based CM (both ionic HOCM and non-ionic LOCM, IOCM) affect the properties of blood, the so-called rheological properties. These effects have been investigated extensively and numerous publications (n = 28) have been published in Acta Radiologica (78)(79)(80)(81)(82)(83)(84)(85)(86)(87)(88)(89).…”

Section: Effects Of Contrast Media On Blood/ Hemorheologic Effectsmentioning

confidence: 99%

Trends in contrast media research the last 100 years

Nielsen

Thomsen

2021

Acta Radiol

View full text Add to dashboard Cite

This review focuses on the trends in contrast media (CM) research published in Acta Radiologica during the last 100 years, since the first edition in 1921. The main topics covered are the developments of iodine- and gadolinium-based CM. Other topics include manganese-based CM for magnetic resonance imaging (MRI) and barium for the investigation of the alimentary tract. From a historic point of view, special CM for use in cholegraphy and myelography are addressed in the review. Today, these imaging procedures are obsolete due to the development of computed tomography, MRI, and ultrasound. The historical use of radioactive thorium-based CM for angiography is also addressed. Furthermore, publications on adverse reactions to CM are reviewed.

show abstract

“…administration. Weiland et al [71] recently performed a randomized controlled trial aimed at comparing the frequency and intensity of discomfort in patients who received i.v. injections of iodixanol and iopamidol for CECT of the abdomen and pelvis.…”

Section: Statement 8 Ct Protocols Should Be Personalized According Tomentioning

confidence: 99%

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

2018

View full text Add to dashboard Cite

Background: The present paper is intended to be a practical guide organized by statements describing methods to reduce risks related to CT examinations in cancer patients. Methods: A panel of radiologists, oncologists and nephrologists were selected based on their publication records in the field and expertise. Ten clinical questions, which were derived from clinical needs and an integration of all the committee members’ suggestions, were stated. The modified Delphi approach was used; it involved a detailed literature review and the collective judgement of experts, including electronic and face-to-face discussions. Results: Ten statements were derived from expert opinions based on the current literature, recently developed guidelines and technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. Conclusion: This paper addresses the clinical implications of performing numerous CT examinations in patients with cancer, providing clinicians with information regarding methods to reduce risk factors in this patient population.

show abstract

Comparison of patient comfort between iodixanol and iopamidol in contrast-enhanced computed tomography of the abdomen and pelvis: a randomized trial

Cited by 8 publications

References 30 publications

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Trends in contrast media research the last 100 years

Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence

Contact Info

Product

Resources

About